NWVCIL Editorial Team

Michigan Attorney General Dana Nessel unveils a groundbreaking transparency dashboard to track every dollar of opioid settlement funds, setting a new national standard for accountability in addiction crisis response.

Mississippi State Department of Health scales innovative addiction treatment program statewide using Epic EHR technology to identify risk earlier and reduce barriers to care in rural communities.

Wisconsin will receive more than $80 million from the $7.4 billion Purdue Pharma and Sackler family settlement, with 70% directed to county and local governments for addiction treatment and prevention programs.

Oregon Health Authority announces $90 million in opioid settlement funding distributed over two years to support prevention, treatment, and recovery services as overdose deaths decline for the second consecutive year.

Attorney General Alan Wilson announces $256 million recovered in opioid litigation settlements, marking a major milestone for addiction treatment and prevention efforts across South Carolina.

New JAMA Network Open research from Yale School of Medicine convenes 42 national experts to develop consensus guidelines for initiating medication-assisted treatment in hospitals as fentanyl transforms clinical protocols

BGSU researchers analyzing syringes from Ohio needle exchange programs discovered dangerous Candida fungus in 86% of samples, plus a soil bacterium that could lead to new treatments

Investigation reveals Indiana municipalities spent over $300,000 of opioid settlement funds on bodycams, vape sensors, and solar eclipse meals instead of addiction treatment.

New Jonesboro facility addresses critical treatment gap in one of Georgia's most underserved regions, offering medically supervised detox and residential care amid rising overdose rates.

Florida reports dramatic 42% decline in opioid-related overdose deaths and 46% drop in fentanyl fatalities, outpacing national improvements and marking significant progress in the state's battle against synthetic opioids.

Clinical trial shows semaglutide plus cognitive behavioral therapy significantly reduces alcohol consumption, offering new hope for treating alcohol use disorder with existing medications.

Ohio's Ibogaine Treatment Study Committee convenes to explore clinical trials for ibogaine-assisted therapy, spurred by Trump's executive order accelerating psychedelic research and veteran advocacy.

New CDC data shows drug overdose deaths fell to approximately 70,000 in 2025, marking three consecutive years of decline from the 2022 peak of nearly 110,000 fatalities.

Preliminary 2025 data shows Oregon overdose deaths fell to approximately 1,100 from 1,544 in 2024, marking the state's first year-over-year decline since 2016.

University of California Davis scientists create new amino acid-based compounds that activate serotonin receptors for mental health benefits without causing hallucinations, potentially revolutionizing addiction and depression therapy.

DEA advisory highlights escalating threat from fentanyl combined with cychlorphine, medetomidine, nitazenes, and xylazine—substances that resist naloxone and are driving overdose deaths across multiple states.

Kentucky launches statewide recovery housing certification program to address housing instability as primary barrier to sustained addiction recovery, setting standards for sober living facilities.

Maine Attorney General Aaron Frey announces $1 million investment from state's $230 million opioid settlement fund to strengthen Mainspring's integrated recovery support model in Kittery.

Milwaukee Public Safety and Health Committee moves forward with comprehensive plan to distribute $17.1 million in opioid settlement funds across prevention, treatment, and recovery services.

Minnesota lawmakers vote 114-15 to legalize regulated psilocybin-assisted therapy, making the state the fourth in the nation to authorize supervised psychedelic treatment for mental health and substance use disorders.

University of Alabama at Birmingham study published in JAMA Network Open finds psilocybin-assisted therapy significantly improved abstinence rates among individuals with cocaine use disorder, offering hope for a condition with no FDA-approved medications.

Flow Neuroscience's tDCS device becomes the first FDA-approved at-home brain stimulation treatment for depression, potentially transforming access to care for millions and offering hope for co-occurring substance use disorders.

Mississippi secures $40.9 million from $7.4 billion Purdue-Sackler settlement, bringing total opioid recovery to over $400 million for addiction treatment and prevention programs.

Mayor Mamdani directs opioid settlement funds to create 500 peer specialist positions, expanding community-based addiction treatment and outreach across all five boroughs.

US authorities issue urgent warning to international visitors ahead of 2026 FIFA World Cup about fentanyl contamination in street drugs, as DEA reports 29% of seized pills contain lethal doses.

New NIH-funded research reveals that oral small-molecule GLP-1 drugs like orforglipron suppress hedonic feeding by modulating the central amygdala, opening potential pathways for treating substance use disorders.

White House releases ambitious 195-page drug control strategy calling for easier treatment access, but administration's funding cuts and policy shifts threaten implementation.

Maryland's highest court rejects 'public nuisance' theory in opioid litigation, forcing Baltimore to dismiss case against McKesson and Cencora while keeping $400 million in earlier settlements.

A deadly synthetic opioid called cychlorphine, estimated to be 10 times more potent than fentanyl and undetectable by standard test strips, has been linked to dozens of overdose deaths across Tennessee, Arkansas, California, and other states.

Michigan achieves a 35% reduction in opioid overdose deaths since 2023, with preliminary 2024 data projecting fewer than 2,000 fatalities through strategic harm reduction investments and naloxone distribution.

Maryland reports a dramatic 57% reduction in opioid overdose deaths since the pandemic peak, reaching a 10-year low through expanded naloxone distribution, fentanyl test strips, and community-based treatment access.

New Hampshire will receive nearly $30 million from the $7.4 billion Purdue Pharma and Sackler family settlement as the historic deal takes effect.

New JAMA Network Open research from Yale brings together 42 national experts to develop consensus guidelines for initiating addiction medications in hospitals as fentanyl transforms treatment protocols

Holyoke, Massachusetts announces inaugural distribution of opioid settlement funds, awarding nearly $1 million to five organizations for recovery coaching, harm reduction, job training, and emergency support.

Healey-Driscoll Administration announces Mosaic Municipal Matching Grants to expand prevention, harm reduction, treatment, and recovery services in communities disproportionately impacted by overdose crisis.

New data shows medication-assisted treatment for opioid use disorder reached 69% among Medicaid beneficiaries by 2023, yet 180-day treatment retention declined from 62.6% to 57.7%.

Colorado Opioid Abatement Council distributes infrastructure grants to 24 organizations, with demand exceeding available funding nearly four to one.

Historic expansion of Wisconsin's oldest women's addiction treatment facility addresses critical waitlist of 100+ people, funded by opioid settlement dollars and private philanthropy.

Wyoming becomes the latest state to adopt digital harm reduction tools, launching an interactive map that connects residents with free naloxone across 22 of 23 counties.

Arizona secures $108 million from the $7.4 billion Purdue-Sackler settlement, bringing the state's total opioid recovery to $1.2 billion amid rising overdose deaths.

Maryland Attorney General Anthony Brown announces $90 million state allocation from $7.4 billion Purdue-Sackler settlement effective May 2026, with funds directed to treatment, prevention, and recovery services.

Pennsylvania Attorney General Dave Sunday announces $200 million state allocation from $7.4 billion Purdue-Sackler settlement, bringing state's total opioid recovery past $2 billion milestone

New Hope Valley facility offers residential detox, trauma therapy, and holistic wellness for Alaska's veterans and active-duty members in a state with the highest per-capita veteran population.

Attorney General Jeff Jackson announces North Carolina's share of $7.4 billion national settlement, bringing state's total opioid recovery funds to $1.6 billion for addiction treatment and prevention.

Texas Attorney General Ken Paxton announces $286.5 million state allocation as $7.4 billion Purdue Pharma settlement takes effect, bringing Texas opioid recoveries past $3 billion milestone

Colorado classrooms are embracing harm reduction strategies and naloxone training, moving away from decades of abstinence-only messaging as fentanyl crisis reshapes youth drug education.

FDA grants priority review vouchers to Compass Pathways, Usona Institute, and Transcend Therapeutics for psilocybin and methylone therapies, marking the most significant federal psychedelic policy advancement in modern American history.

Nevada expects $57.9 million over 15 years from the $7.4 billion Purdue Pharma and Sackler family settlement, bringing the state's total opioid settlement recovery to over $1.2 billion.

Trump administration ends federal support for fentanyl, xylazine, and medetomidine test strips through SAMHSA grants, reversing Biden-era harm reduction policies amid declining overdose deaths.

South Carolina to receive $72.8 million over 15 years as $7.4 billion Purdue Pharma and Sackler family settlement takes effect, bringing total state recovery to over $750 million.

Austin-area officials credit free naloxone distribution through vending machines and community partnerships for dramatic reduction in fentanyl fatalities.

Kentucky reports fourth straight year of declining overdose deaths with 22.9% reduction in 2025, marking 50.8% decrease from 2021 peak as comprehensive state strategy shows sustained results.

The historic $7.4 billion Purdue Pharma and Sackler family settlement becomes legally effective May 1, 2026, with states beginning to receive funds for addiction treatment and prevention programs.

Trump administration proposes national wastewater monitoring and artificial intelligence to track drug use patterns, alongside faith-based treatment expansion and integrated addiction care.

New CDC data shows U.S. overdose deaths fell 15.9% in the past year, but emerging synthetic drugs like medetomidine threaten continued progress

While overdose deaths fell 18% nationally, Colorado saw a 10% increase in fentanyl-related fatalities, with Denver reporting a 25% spike. DEA data reveals the state's unique challenges.

Nebraska will require Medicaid expansion enrollees to work 80 hours monthly, raising concerns about addiction treatment access for vulnerable populations.

Federal court sentences OxyContin maker to historic penalties, clearing path for bankruptcy settlement that includes $865 million for victims—but many will be shut out under tightened eligibility rules.

Researchers analyze 569,000 TikTok comments to demonstrate social media data can forecast synthetic opioid mortality with 37% greater accuracy than traditional surveillance methods.

Eden Village uses $140,000 in opioid settlement grants to provide permanent supportive housing and peer counseling for chronically homeless individuals recovering from addiction.

Georgia's Opioid Crisis Abatement Trust opens applications for Year 3 funding, allocating $20 million to address addiction and overdose across the state.

Physicians publish urgent editorial urging federal action to protect access to addiction medications during climate emergencies after Hurricane Helene exposed critical gaps.

Local governments in South Dakota struggle to deploy opioid settlement dollars while the state moves faster with grants and programs, highlighting challenges rural areas face in addressing the addiction crisis.

Iowa Attorney General Brenna Bird announces $9 million in opioid settlement grants for community prevention and treatment programs, with funds flowing through state legislature-approved distribution framework.

Rural Oklahoma faces barriers accessing opioid settlement grants due to lack of grant-writing expertise and community partnerships, while metro areas and schools secure most funding.

Trump administration's SAMHSA announces major policy reversal, banning federal funds for fentanyl test strips and sterile syringes while urging limitations on methadone and buprenorphine prescribing.

Milwaukee County reports dramatic 42.5% decline in drug overdose deaths since 2022, driven by harm reduction expansion, medication-assisted treatment, and $111 million opioid settlement investment.

Vermont reports dramatic 25% reduction in drug overdose deaths, marking the state's first significant decline in fatal overdoses in 20 years amid national mortality improvements.

West Virginia reports 48% drop in fatal drug overdoses, exceeding the national decline of 44%, as enforcement and public health efforts converge in the state hardest hit by the opioid crisis.

Kentucky Opioid Abatement Advisory Commission distributes record $34 million to 100+ organizations, bringing total community investment past $100 million since 2021.

Health officials confirm first fatal overdose involving N-Propionitrile chlorphine, a potent synthetic opioid undetectable by standard fentanyl test strips.

New data presented at ASAM 2026 shows extended-release buprenorphine (Sublocade) associated with lowest overdose rates among medication options and supports remission as meaningful treatment endpoint.

Utah joins $773.7 million national settlement with Albertsons Companies, directing funds to opioid abatement programs for treatment, recovery services, and prevention efforts.

FDA awards priority review vouchers to Compass Pathways, Usona Institute, and Transcend Therapeutics for psilocybin and methylone therapies targeting treatment-resistant depression and PTSD.

State regulations force daily clinic visits and limit take-home doses, making medication-assisted treatment more burdensome than federal standards require.

New research published in JAMA shows the 988 suicide crisis hotline is associated with significant reductions in suicide deaths among young people, with states showing highest call volume experiencing the greatest declines.

New Mexico becomes testing ground for SAMHSA-vetted digital recovery platform with dedicated teen version, offering 24/7 peer support and crisis intervention through smartphones.

New Child Trends analysis shows youth overdose deaths dropped 37% since 2023, with rates now lower than before the pandemic despite fentanyl's continued spread.

Mayor Brandon Scott unveils first annual report and public dashboard tracking how Baltimore invests settlement dollars from opioid litigation into harm reduction, treatment, and community services.

State Senator Pat McMath proposes using unspent opioid settlement dollars to fund clinical research into psychedelic-assisted therapy for veterans, first responders, and people with opioid dependence.

New JAMA Network Open study shows MOUD access among Medicaid beneficiaries rose from 60% to 69% between 2019-2023, with 45 states seeing increases.

DEA identifies carfentanil 1,400 times in 2025 drug seizures as the ultra-potent synthetic opioid 100 times stronger than fentanyl kills hundreds across 42 states.

In a region flooded with 17 million prescription opioids, proposed Medicaid work requirements and funding cuts threaten to dismantle the safety net that has helped hundreds achieve recovery from addiction.

Albertsons and Safeway parent company agrees to $773 million national settlement, with Oregon receiving up to $38.2 million over nine years to expand addiction and recovery services.

UC San Diego and SDSU study of 2.8 million students finds local flavor bans reduce e-cigarette use by 20% with no increase in cigarette smoking, challenging industry arguments.

New research reveals 20% of US pharmacies block access to buprenorphine, with independent pharmacies and southern states showing significantly higher refusal rates for this life-saving opioid addiction medication.

Wake Forest research reveals e-cigarette taxes reduced vaping among heterosexual teens by 3-4 percentage points, yet had no effect on LGBQ youth who use nicotine to cope with bullying and emotional distress.

JAMA research letter reveals 24.3% decline in long-term opioid therapy from 2015-2023, even as co-prescribing with gabapentinoids rises sharply, raising new safety concerns for chronic pain patients.

South Dakota distributes second round of transformative grants to 10 organizations, funding mobile street medicine, recovery coaching for incarcerated individuals, and primary care addiction training.

President Trump signs executive order directing FDA to fast-track psychedelic drug reviews, allocates $50 million for ibogaine research, and establishes Right to Try pathway for treatment-resistant patients.

New ASAM Criteria volume establishes dedicated clinical standards for youth SUD treatment, emphasizing brain development, family engagement, and integrated mental health care

BMJ study of 2.5 million Medicaid births finds children exposed to buprenorphine in utero have no greater risk of ADHD, autism, or other neurodevelopmental disorders compared to methadone exposure.

DEA reports 1,400 carfentanil identifications in 2025, up from just 54 in 2022. The veterinary tranquilizer, 100 times stronger than fentanyl, is killing unsuspecting users as China cracks down on fentanyl precursors.

JAMA Network Open study finds Medicaid expansion in eight states increased buprenorphine prescriptions by over 21%, with Oklahoma seeing 43% drop in overdose deaths.

President Trump signs executive order directing FDA to fast-track psychedelic research, provides $50 million for ibogaine studies, and opens Right to Try pathway for patients with treatment-resistant mental illness.

The Trump administration abruptly canceled hundreds of SAMHSA grants funding overdose prevention, naloxone distribution, and peer recovery support, putting addiction services at risk nationwide.

Twenty Kentucky counties join forces through the KACo Opioid Solutions Network to share best practices and strategically deploy nearly $1 billion in settlement funds

White House budget request would slash drug prevention grants, consolidate SAMHSA into new agency, and merge NIDA with alcohol institute while cutting $200 million from research.

Advocates press Congress to expand Veterans Treatment Courts and restore VA benefits access for incarcerated veterans struggling with service-connected mental health and substance use disorders

More than 200 residents protest proposed 122-bed addiction treatment facility funded by California's Proposition 1, highlighting tensions between statewide mental health expansion and neighborhood concerns

New research in Journal of Psychiatric Research reveals individuals with opioid use disorder face 1.88 to 4.17 times greater odds of suicidal thoughts, with moderate cases showing highest attempt rates.

ONDCP, SAMHSA and HUD launch two-day summit to develop national toolkit for treating substance use disorders among homeless individuals, marking a shift toward integrated care models

Federal health officials warn about medetomidine, a veterinary tranquilizer increasingly mixed with illicit fentanyl, causing complex withdrawal syndromes and complicating overdose responses

New Anesthesiology research reveals that conventional naloxone doses may not fully reverse respiratory depression from potent synthetic opioids like fentanyl and sufentanil, urging updated emergency protocols

Food and Drug Administration issues complete response letter rejecting Lykos Therapeutics' MDMA-assisted therapy for PTSD, demanding additional clinical trials despite promising efficacy data.

New JAMA study shows states expanding Medicaid after 2018 saw sharp rises in buprenorphine prescriptions, but federal funding cuts could reverse gains.

Wisconsin Department of Health Services announces comprehensive $31 million opioid response strategy combining treatment access expansion, harm reduction, and law enforcement education.

New BMJ research finds semaglutide and similar medications associated with 14% reduced risk of developing substance use disorders and 50% fewer deaths among veterans already in treatment.

Michigan's MDHHS accepting applications through April 30 for loan repayment up to $30,000 to SUD providers as state confronts workforce shortage limiting treatment access for 1.3 million residents.

North Carolina awards federal block grants to 12 community organizations for rural treatment, crisis response, and justice-involved recovery programs targeting 1.4 million residents with substance use disorders.

World Health Organization updates opioid dependence treatment recommendations, conditionally endorsing monthly injectable buprenorphine formulations as global treatment gap persists.

Central Health plans 45 free naloxone units by September as Travis County overdose deaths drop 22%, expanding vending machines and community partnerships to sustain decline.

Northwestern University researchers debunk 2025 drug overdose surge reported by CDC, finding the apparent spike was a modeling error caused by rapid epidemic shifts, not data manipulation or political interference.

Rhode Island becomes first state to reverse kratom ban while Kansas, Connecticut move toward Schedule I classification, creating fragmented regulatory landscape for substance used by millions for pain and opioid withdrawal.

Intravenous DMT reduced depressive symptoms within a week in Phase IIa trial, with effects lasting up to three months, according to study published in Nature Medicine.

Congressional bill H.R. 5629 threatens to roll back SAMHSA's permanent methadone take-home flexibilities as Pew Charitable Trusts submits testimony defending COVID-era reforms that reduced travel burdens without increasing diversion or deaths.

NCDHHS awards federal block grant funding to twelve community organizations targeting rural areas, youth prevention, and criminal justice-involved populations as state battles 1.4 million struggling with substance use.

National coalition urges Congress to maintain SAMHSA, NIH, and addiction program funding in FY2027 appropriations amid proposed 12.5% HHS budget cuts.

House roundtable examines paradox of doubled treatment access, 241% spending increase while depression and suicide reach historic highs. Youth antidepressant prescriptions jump 63%.

World Health Organization updates treatment guidelines adding monthly buprenorphine injections to methadone oral medication recommendations addressing epidemic killing three-quarters million people yearly

Longleaf Lodge launches with 50 residential and 10 detox beds, addressing Alabama's crisis where 19% need substance use treatment but only 5% receive it. Integrated care model tackles co-occurring conditions as wait times stretch weeks to months.

Federal initiative targets individuals experiencing homelessness and substance use disorders through outcomes-based approach, but faith-based inclusion and punitive policy context raise concerns among public health advocates.

Second round of 'transformative grants' prioritizes youth treatment expansion, school prevention programs, and mobile crisis response as state officials emphasize building complete care continuum

Mississippi, Tennessee, Texas, West Virginia, Oklahoma, and Missouri are coordinating clinical trials of ibogaine—a Schedule I psychedelic—for opioid addiction and PTSD despite federal restrictions.

Deal flow in substance use disorder treatment hits six-year low as investors pull back amid quality concerns, Medicaid uncertainty, and volatile federal grants—leaving safety-net providers facing potential closures.

SB 365 would mandate ERs provide evidence-based addiction treatment, potentially saving $20,000 per patient annually while reducing overdose deaths — but faces hospital pushback over costs.

World Health Organization adds conditional recommendation for monthly and weekly buprenorphine injections, expanding evidence-based options for 61 million people using opioids non-medically worldwide.

Two competing bills represent fundamentally different approaches to kratom policy—one seeks complete prohibition while the other acknowledges harm reduction uses for addiction recovery and pain management.

Despite receiving $800 million since 2023, more than 40% of Michigan counties have yet to distribute opioid crisis mitigation funds while overdose deaths continue claiming nearly 2,000 lives annually.

Governor Rhoden announces funding for 10 organizations as Attorney General Jackley pushes for direct allocation to Sioux Falls and Rapid City treatment centers.

University of Cincinnati launches one of nation's largest trials pairing weight-loss drugs with proven addiction medication to improve treatment retention and reduce cravings.

New research from Ohio University finds primary care physicians view opioid use disorder as more treatable than diabetes, yet only 8% have ever prescribed buprenorphine, creating treatment deserts in rural America.

World Health Organization adds conditional endorsement for long-acting injectable buprenorphine to global opioid dependence treatment guidelines April 2026, alongside continued strong recommendations for methadone and oral formulations.

Proposed legislation SB 365 mandates that Connecticut emergency departments offer buprenorphine to patients with opioid use disorder, despite hospital opposition citing costs.

Senator Patty Murray announces funding for Tacoma-Pierce County mobile medical services while highlighting successful pushback against Trump administration's proposed $2 billion SAMHSA grant terminations.

Ann Arbor-based online addiction provider now treats kratom and 7-hydroxymitragynine dependence through app-based platform, addressing regulatory gap as FDA restricts potent derivatives but leaf products remain unregulated nationwide.

Georgia county awards settlement dollars to programs ranging from peer support to residential treatment as officials confront third-highest opioid death toll in the state.

New report profiles eight alternative mental health crisis programs removing police from response while Trump administration restructuring threatens federal funding infrastructure.

State lawmakers advance plan to distribute nearly $60 million in opioid settlement money, sidestepping the independent council created just last year to oversee spending.

University of Pennsylvania researchers develop first brain-targeted gene therapy that mimics morphine's pain relief without triggering reward pathways, offering potential breakthrough for 50 million Americans living with chronic pain.

Federal agency proposes expanding community health workers and peer support specialists in rural areas where 60% of Americans lack access to mental health and addiction treatment services.

WVU leads 18-month statewide assessment to guide how three-quarters of West Virginia's opioid settlement funds will be spent, creating public dashboard to identify gaps and maximize impact.

American Society of Addiction Medicine releases first comprehensive update to youth substance use disorder treatment standards in over a decade, addressing telehealth, trauma-informed care, and medication access.

Kentucky Senate Bill 77 nears final passage, creating framework to research ibogaine for opioid addiction and PTSD despite Schedule I status. Four states already funding trials.

State officials unveil plan to restructure troubled mental health agency, potentially dissolving it and shifting control to Department of Health as providers struggle with service cuts.

Congressional oversight hearing exposes chaotic federal response to addiction crisis as $2 billion in treatment grants remain uncertain and agency staff cut by half

Swedish registry analysis of 100,000 individuals finds GLP-1 medications reduce depression by 44%, anxiety by 38%, and substance use disorders by 47%.

Oregon and Colorado lead regulated psilocybin therapy programs as research shows promise for depression, PTSD, and addiction. Personal stories reveal profound results.

Indiana University's MACRO-B initiative reduced opioid overdose mortality among Black Indianapolis residents by 45% in two years, now expanding statewide.

New Nature Mental Health study finds combining low-dose ketamine with mindfulness training improves outcomes for people receiving buprenorphine treatment, opening door to psychedelic-assisted interventions

Cychlorphine, a novel opioid resistant to standard naloxone doses, has been detected in over a dozen states. Oklahoma confirmed its first death as experts warn the drug may require multiple Narcan doses to reverse overdoses.

Governor Josh Stein announces expansion of Law Enforcement Assisted Diversion programs to seven counties, offering treatment alternatives to incarceration for low-level offenses involving substance use.

New Wisconsin Policy Forum report reveals dramatic expansion in MOUD access across state correctional facilities from 2021 to 2025, coinciding with substantial decline in overdose deaths.

AB 602 requires California public universities to provide addiction treatment rather than punishment when students seek help for overdoses, effective July 2026.

CDCR documented over 7,000 overdose reversals since 2019 and became the only U.S. state prison system allowing incarcerated individuals to carry naloxone inside facilities.

SUPPORT Act allows pharmacists to prescribe addiction medication with 8 hours training. Maryland considers state legislation as federal pathway opens treatment access.

National opioid overdose deaths fell to 46,066 in October 2025, down from 86,075 in June 2023. CDC data reveals declines across all racial groups as weaker fentanyl supply and expanded treatment efforts reshape the crisis.

Federal $750K investment establishes Pennsylvania Addiction Action Network to coordinate data-driven opioid settlement spending across all 67 counties

Opioid deaths fell 12% in Washington last year while innovative programs expanded access to life-saving treatment. But new Medicaid work requirements and federal funding cuts are already disrupting care.

Survey of 212 U.S. jails, prisons, and detention centers finds stark regional and facility-type disparities in MOUD access, with post-release mortality 40 times higher than national average.

Psychostimulants, primarily methamphetamine, overtook opioids as Iowa's leading overdose cause in 2024. Without a Narcan equivalent, public health officials confront new treatment challenges.

Veterinary sedative 300× more potent than xylazine spreads through illicit opioid supply, causing life-threatening withdrawal and evading standard drug tests.

Baltimore's finalized Overdose Response Strategic Plan ups its target to a 50% reduction by 2040, backed by nearly $600 million in opioid settlement funds and community-driven priorities.

Workit Health's evidence-based virtual care model delivers 62% rural retention at three months—more than double competing programs—with peer-reviewed studies in JAMA Network Open showing perfect buprenorphine adherence among participants.

Eastern Shoshone Tribal Health launches Wyoming's first harm reduction vending machines offering free naloxone, fentanyl test strips, and suicide prevention tools through anonymous PIN access to address overdose crisis on Wind River Reservation.

Bipartisan DETECT Nitazenes Act introduced in Congress would enhance detection technology for emerging class of synthetic opioids linked to over 1,000 deaths in UK.

First randomized trial testing extended-release buprenorphine in pregnancy finds higher abstinence rates and fewer serious adverse events compared to standard sublingual treatment.

West Virginia First Foundation introduces Regional Contingency Allocation Program allowing six regions to respond to immediate community needs outside traditional grant cycles, managing nearly $1 billion in settlement funds.

Columbia adds twelve public naloxone boxes as Missouri House proposes $8M cut to statewide distribution, threatening 800 agencies and 7,500 documented overdose saves since 2017.

New federal data reveals historic decline in opioid deaths across all demographics, driven by expanded naloxone access, weaker fentanyl supply, and medication treatment—though Arizona and four other states buck the trend.

Brandeis University economic analysis shows two pharmacy-based methadone models generate positive returns of $2.64 and $3.53 per dollar spent over three years while addressing treatment deserts in 80% of U.S. counties.

Federal funding establishes Pennsylvania Addiction Action Network to coordinate data-driven allocation of settlement funds across all 67 counties as state confronts 4,719 annual overdose deaths.

Somerset County commissioners chose to protect a jail Sublocade program with zero overdose deaths over prevention services as opioid settlement funds run short.

ACLU challenges West Virginia's 2007 moratorium on methadone clinics, arguing the state's unique restriction violates disability law while forcing 54,000 residents with opioid use disorder to navigate impossible treatment logistics.

A new survey of 212 jails and prisons finds only 58% provide FDA-approved medications for opioid use disorder, with stark regional disparities and treatment gaps putting released inmates at 40-times-higher overdose risk.

Senate Bill 2185 passed committee and would mandate MAT screening and access in all Illinois prisons, funded by opioid settlements, following a Kane County program that cut overdose deaths by 89%.

Mayor Daniel Lurie announces Proposition 1 funding for 100 new psychiatric and addiction treatment beds across three sites, even as the city faces $900 million deficit and federal funding cuts.

Parents who lost children to overdoses are urging Pennsylvania to use settlement money to create a comprehensive bereavement support system modeled on Philadelphia's Philly HEALs program.

NIH-funded trial finds pregnant patients receiving weekly extended-release buprenorphine injections achieved significantly higher rates of opioid abstinence with fewer serious adverse events than those on sublingual buprenorphine.

SAMHSA's termination and rapid restoration of $2 billion in mental health grants in January exposed fragility of addiction infrastructure as overdose deaths decline for first time in decades.

New research shows patients adherent to extended-release buprenorphine injections had $15,017 lower annual costs and fewer emergency visits than those using other opioid use disorder medications.

New study finds NET Device reduces opioid and stimulant use for 3 months post-treatment, offering hope for polysubstance addiction amid no approved medications for stimulants

AG Kris Kobach and DCCCA deploy free overdose reversal kits across Kansas universities and community colleges as state battles 2,000+ fentanyl deaths.

New transparency tool shows municipalities spent just 12% of available settlement funds in latest fiscal year, while state officials emphasize accountability in managing $1 billion expected through 2039.

New Oregon laws streamline licensing, strengthen workplace safety, and expand access to mental health and addiction services amid one of the nation's worst provider shortages

University of Arizona trial finds 73% of participants responded to multiple psilocybin sessions, with 40% achieving remission from obsessive-compulsive disorder symptoms lasting six months.

Cychlorphine, an emerging synthetic opioid more potent than fentanyl, has been connected to at least 16 overdose deaths in East Tennessee since October. Federal authorities track 22 samples nationwide as harm reduction officials warn naloxone may require multiple doses.

Lawmakers push package of reforms including 988 funding, treatment bed registry, and insurance coverage mandates as state struggles to meet crisis response needs.

CDC data shows overdose deaths fell to 68,000 in 12 months ending October 2025, the lowest since 2019, driven by a dramatic decline in fentanyl purity from 25% to 11% as all four waves of the epidemic enter simultaneous decline.

Eight new mental health and drug treatment facilities will receive Proposition 1 funding, including sobering centers and residential programs across the Bay Area

VA study of 600,000 patients finds GLP-1 medications like Ozempic reduce substance use disorder risk by 15-20%, suggesting a common biological pathway underlying all addictions.

New CDC data reveals West Virginia and Virginia achieved the steepest opioid death declines in America, with drops approaching 49% and outpacing the national 44% reduction.

Bipartisan POINTS Act would allocate $100M annually from sports betting taxes to prevention and treatment programs, marking the first dedicated federal investment in gambling disorder services.

Indiana city's first round of settlement funding prioritizes community organizations meeting people at every stage of recovery, including grief counseling for families navigating substance use loss.

Sen. John Keenan proposes expanding subway naloxone access after 2024 pilot ended prematurely, leaving empty and broken cabinets across Boston's transit system.

New state transparency dashboard reveals municipalities spent just 12% of available settlement funds in FY2025 while communities await critical addiction services and harm reduction programs.

Minnesota lawmakers approved HF 2906, creating a state-regulated psilocybin therapy pilot program with patient caps and bipartisan backing, joining Oregon and Colorado.

City Council approves five-year opioid settlement funding plan targeting overdose prevention through community-based Narcan distribution, HIV testing, and integrated harm reduction services.

Maine city finally distributes nearly all available settlement money to 16 organizations, three years after receiving first payments, as Penobscot County sees rising overdose deaths.

State lawmakers unanimously approve evidence-based mandates and conflict-of-interest safeguards for $400M+ opioid settlement fund after investigative reporting exposed governance failures.

Harm Reduction Coalition of San Diego failed to pay subcontractors and staff for months while COO allegedly misappropriated over $200,000 in public funds for personal expenses.

Federal judge's ruling forces Education Department to restore funding for 120 school mental health projects, extending support through June 2026 as legal battle continues.

JAMA Network Open study analyzing Medicare records shows specialists using telemedicine heavily saw only 0.9% more rural patients while treating 3.6% fewer new patients overall.

New national survey reveals 18 states mandate recovery assessments in treatment facilities, but federal reporting burdens and staffing shortages slow broader adoption.

Federal agency opens funding applications for children's mental health services, suicide prevention frameworks, and assisted outpatient treatment programs as part of broader recovery initiative.

Governor Newsom awards funding to 28 regions while launching accountability system recognizing 'CARE Champions' and placing underperforming counties in intensive support program.

Mississippi Senate passes HB 314, allocating $5M from opioid settlement funds to join Texas and Arizona in FDA clinical trials of ibogaine for opioid addiction and PTSD treatment.

Weill Cornell research shows state laws eliminating insurance prior authorization for buprenorphine don't significantly improve 180-day retention rates, highlighting need for broader policy interventions.

MDHHS distributes free naloxone kits at local offices statewide, funded by $1.8 billion opioid settlement. State reports 35% decline in overdose deaths since 2023.

While Mississippi sits on over $400 million in opioid settlement funds, the state has spent almost none of it on treatment or family services — even as it leads the nation in children living with grandparents and foster care tied to parental substance use.

Civil rights lawsuit alleges Missouri DOC and Centurion Health deny life-saving medication to prisoners with opioid use disorder, despite $7M in settlement funds and rampant drug availability.

Washington University analysis of 600,000+ VA patients finds GLP-1s tied to 50% reduction in drug-related deaths and lower risk across alcohol, opioid, cocaine, and nicotine use disorders.

Washington University research shows uMAT-R app reduced opioid and drug use by 50% in people experiencing housing insecurity, addressing critical gap in treatment access.

New research identifies myelin remodeling as the missing link between short-term psychedelic experiences and long-term PTSD relief, shifting focus from neurons to oligodendrocytes.

House Bill 487 allocates $43M from opioid settlements to prevention, treatment, and recovery programs, with unanimous bipartisan support as Alabama reports 30% reduction in overdose deaths.

Local governments in Maine allocated $3 million from opioid settlements in 2025 toward treatment, prevention, and law enforcement programs, with $19 million remaining and new reporting requirements now in place.

State legislators advance $5.7 million appropriation to sustain 988 Mental Health Lifeline after federal funding expires in September, citing success in diverting crisis calls from emergency services.

New federal legislation would require OSHA guidance on workplace naloxone access amid rising employer reports of opioid impact and uneven emergency preparedness.

Missouri's Veterans Mental Health Innovation Act would fund FDA ibogaine clinical trials for opioid use disorder and traumatic brain injury, joining Texas and Arizona in breakthrough therapy research.

State programs like Project Nurture combine prenatal care, substance use treatment, and peer support after Oregon data showed mental health and SUD led pregnancy-related deaths.

The Maternal Overdose Matters Initiative delivered naloxone kits to over 2,500 families at 107 hospitals, helping reverse a crisis where overdose became the leading cause of maternal mortality statewide.

In a landmark policy shift, the FDA announced it will approve new drugs based on a single rigorous trial plus confirmatory evidence—a change that could accelerate development of therapies for opioid use disorder, alcohol addiction, and stimulant dependence.

DEA and HHS codify pandemic-era flexibility, allowing providers to initiate and maintain buprenorphine treatment entirely via telehealth through the end of 2026, a move experts say could save lives and reshape addiction care nationwide.

California's CalRx program cuts naloxone costs by more than half while the state's distribution initiative crosses a staggering milestone in overdose reversals.

The Food and Drug Administration moves forward with controversial regulations to limit common painkillers, sparking national debate over balancing opioid crisis response with patient access to pain management.

As cocaine and methamphetamine become contaminated with fentanyl, researchers argue that contingency management and culturally adapted harm reduction are essential—yet remain vastly underutilized across the United States.

Imperial College London study published in Nature finds that a single 30-minute DMT session with therapeutic support reduced depressive symptoms more effectively than placebo, marking another step forward for psychedelic-assisted mental health treatment.

Digital therapeutics for substance use disorders are gaining traction as researchers identify key strategies to improve engagement and outcomes, with apps reaching patients beyond traditional clinic walls.

New research from Harvard Medical School shows that just 10 yoga sessions can reduce the most severe phase of opioid withdrawal from nine days to five, offering a promising tool for addiction recovery.

New federal rules allow providers to prescribe six-month supply of buprenorphine via audio-only telehealth for opioid use disorder treatment, eliminating pandemic-era restrictions while implementing safeguards.

Senate Bill 2749 passes committee with unanimous vote, expanding Illinois' addiction treatment framework to include problem gambling and mandating new prevention and recovery services statewide.

Washington University study finds that uMAT-R digital platform reduced substance use by 50% among participants with housing instability, challenging assumptions about technology access in vulnerable populations.

New Jersey lawmakers unanimously approve trio of bills to regulate addiction treatment industry, addressing concerns raised in 2024 state investigation into facility operations and peer recovery programs.